- Report
- January 2024
- 175 Pages
Global
From €4870EUR$5,000USD£4,163GBP
- Report
- January 2024
- 175 Pages
Global
From €4870EUR$5,000USD£4,163GBP
- Report
- November 2023
- 138 Pages
Global
From €2434EUR$2,499USD£2,081GBP
- Report
- February 2020
- 237 Pages
Global
From €1339EUR$1,375USD£1,145GBP
€2678EUR$2,750USD£2,290GBP
- Report
- April 2018
- 112 Pages
Global
From €4577EUR$4,700USD£3,913GBP
- Report
- May 2021
- 87 Pages
Global
€21426EUR$22,000USD£18,319GBP
- Report
- June 2019
Global
From €7304EUR$7,500USD£6,245GBP
- Book
- January 2020
North America
- Book
- March 2018
North America
Hyperglycemia is a medical condition in which an individual has an abnormally high level of glucose in their blood. It is a common symptom of diabetes, a chronic endocrine disorder that affects the body's ability to produce or use insulin. Hyperglycemia can lead to serious health complications, including heart disease, stroke, and kidney failure. Treatment for hyperglycemia typically involves lifestyle changes, such as diet and exercise, as well as medications to help control blood sugar levels.
The hyperglycemia market is a subset of the endocrinology market, which focuses on the diagnosis and treatment of endocrine disorders. This market is driven by the increasing prevalence of diabetes and other endocrine disorders, as well as the development of new treatments and technologies. Companies in this market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Show Less Read more